{
    "body": "LY450139 is investigational name of which drug?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/19692615", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20350302", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22710916", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22018341", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23278303", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19527190", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22778845", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20634579"
    ], 
    "ideal_answer": [
        "LY450139 is investigational name of Semagacestat. It is a \u03b3-secretase inhibitor developed for treatment for Alzheimer's disease. Chemical name of LY450139 is hydroxylvaleryl monobenzocaprolactam."
    ], 
    "exact_answer": [
        "semagacestat"
    ], 
    "concepts": [
        "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015507"
    ], 
    "type": "factoid", 
    "id": "54f35ad864850a5854000004", 
    "snippets": [
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 213, 
            "text": "The outcomes of the clinical trials of the \u03b3-secretase inhibitor Semagacestat (LY-450139) and the \u03b3-secretase modulator (GSM) Tarenflurbil were disappointing, but may not represent the end of the \u03b3-secretase era. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22710916", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 681, 
            "offsetInEndSection": 804, 
            "text": "A selective BACE inhibitor and the \u03b3-secretase inhibitor LY450139 (semagacestat) were used to inhibit respective secretase.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22018341", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": -1, 
            "offsetInEndSection": 71, 
            "text": "ACS chemical neuroscience molecule spotlight on semagacestat (LY450139).", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22778845", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 173, 
            "text": "Semagacestat (LY450139) is a novel \u03b3-secretase inhibitor currently in late-stage development by Eli Lilly and Company as a potential treatment for Alzheimer's disease (AD). ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22778845", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 184, 
            "offsetInEndSection": 358, 
            "text": " The \u03b3-secretase inhibitor LY450139 (semagacestat) lowers plasma A\u03b2(1-40) and A\u03b2(1-42) in a dose-dependent manner but has no clear effect on the CSF level of these isoforms. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20634579", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 2, 
            "offsetInEndSection": 176, 
            "text": "TRODUCTION: LY450139 (semagacestat) inhibits gamma-secretase, a key enzyme for generation of amyloid beta (Abeta), the peptide deposited in plaques in Alzheimer disease (AD).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20350302", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 553, 
            "offsetInEndSection": 801, 
            "text": "Two potent gamma-secretase inhibitors (GSIs), DAPT (N-[N-(3,5-difluorophenacetyl-L-alanyl)]-S-phenylglycine t-butyl ester) and LY450139 (hydroxylvaleryl monobenzocaprolactam), were found to reduce the density of dendritic spines in wild-type mice. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19692615", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 2, 
            "offsetInEndSection": 121, 
            "text": "velopment of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19527190", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 269, 
            "offsetInEndSection": 391, 
            "text": "OBJECTIVE: This paper reviews the pharmacology and chemical efficacy of an A beta-lowering agent, semagacestat (LY450139).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19527190", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 72, 
            "text": "ACS chemical neuroscience molecule spotlight on semagacestat (LY450139).", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22778845", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 653, 
            "offsetInEndSection": 777, 
            "text": " A selective BACE inhibitor and the \u03b3-secretase inhibitor LY450139 (semagacestat) were used to inhibit respective secretase.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22018341", 
            "endSection": "abstract"
        }
    ]
}